#### REVIEW



# A comparison of perioperative outcomes of transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a systematic review

Ali Bourgi<sup>1</sup> · Elias Ayoub<sup>2</sup> · Sleiman Merhej<sup>3</sup> · Josee Souky<sup>1,2,3,4</sup> · Morgan Roupret<sup>4</sup> · Franck Bruyère<sup>1</sup>

Received: 4 March 2022 / Accepted: 16 July 2023 / Published online: 18 August 2023 © The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2023

#### Abstract

RAPN can be carried out via a transperitoneal or retroperitoneal approach. The choice between the two approaches is open to debate and usually based on surgeon preference. The perioperative outcomes of transperitoneal robot-assisted partial nephrectomy versus retroperitoneal robot-assisted partial nephrectomy were compared. A systematic review of the literature was performed up to May 2020, using PubMed, Cochrane, Scopus and Ovid databases. Articles were selected according to a search strategy based on PRISMA criteria. Only studies comparing TRAPN with RRAPN were eligible for inclusion. Eleven studies were included in the quantitative synthesis. Baseline demographics (age, BMI, ASA, tumour size, and RENAL nephrometry score), intraoperative data (operative time, estimated blood loss, and warm ischaemia time) and postoperative outcomes (major complications according to Clavien-Dindo, length of hospital stay (LOS) and positive surgical margin rate) were recorded. A total of 3139 patients were included (2052 TRAPN vs. 1087 RRAPN). There was no significant difference in demographic variables (age, BMI), tumour size (p = 0.06) nor the nephrometry score (p = 0.20) between the two groups. Operative time (p = 0.02), estimated blood loss (p < 0.00001) and LOS (p < 0.00001) were significantly lower in the RRAPN group. No differences were found in major postoperative complications (Clavien–Dindo>3; p=0.37), warm ischaemia time (p=0.37) or positive surgical margins (p=0.13). Future researchers must attempt to achieve adequately powered, expertise based, multi-surgeon and multi-centric studies comparing TRAPN and RRAPN. RRAPN gives similar outcomes to TRAPN. RRAPN is associated with reduced operative time and LOS. Ideally, surgeons should be familiar and competent in both RAPN approaches and adopt a risk-stratified and patient-centred individualised approach, dependent on the tumour and patient characteristics. RAPN is feasible via two approaches. The retroperitoneal approach seems to be associated with a shorter operation time and hospital stay.

Keywords Partial nephrectomy · Transperitoneal · Retroperitoneal · Robotic surgery

Ali Bourgi alibourgi@gmail.com

Elias Ayoub eayoub87@gmail.com

Sleiman Merhej lec@dm.net.lb

Morgan Roupret morgan.roupret@aphp.fr

Franck Bruyère f.bruyere@chu-tours.fr

- <sup>1</sup> Department of Urology, University Hospital of Tours, 2 Boulevard Tonnellé, Tours, Loire Valley, France
- <sup>2</sup> Department of Urology, chu Poitiers, Poitiers, France
- <sup>3</sup> Department of Urology, Saint Joseph University, Damascus Road, PO-BOX: 17-5208, Beirut, Lebanon
- <sup>4</sup> Department of Urology, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France

# Introduction

The increased use of diagnostic imaging over the last decade has contributed to the diagnosis of a greater number of asymptomatic renal masses [1]. These tumours (most often classified as T1a or T1b) are candidates for nephron-sparing surgery. Nowadays, partial nephrectomy is considered the gold standard for T1a tumours, for most T1b tumours and even for highly selected T2 tumours [2–4].

Laparoscopic partial nephrectomy (retroperitoneal or transperitoneal) has been adopted in some tertiary centres seeking minimal invasive techniques. This procedure offers similar functional and oncological outcomes to open partial nephrectomy, with less blood loss and a shorter hospital stay. Nevertheless, its use is restricted to specialised experienced laparoscopic surgeons due to its steep learning curve [5, 6]. The development of robot-assisted surgery (DaVinci robot; Intuitive Surgical, Sunnyvale, CA) has overcome the disadvantages of the standard laparoscopic approach, improving instrument movement and enabling easy working and suturing, even in confined spaces [7, 8].

In 2010, a relative annual increase of 45.4% was noted for robot-assisted laparoscopic partial nephrectomy, whereas open and laparoscopic partial nephrectomy increased by 7.9% and 6.1%, respectively [9]. Nowadays, robot-assisted partial nephrectomy (RAPN) has become the surgical intervention of choice for renal masses suitable for a nephronsparing approach [10].

RAPN can be carried out via a transperitoneal or retroperitoneal approach. The transperitoneal approach is preferred in laparoscopic partial nephrectomy due to a larger working space and better recognition of anatomical structures. The choice between the two approaches is open to debate and usually based on surgeon preference.

The retroperitoneal approach has been popularised as it avoids the peritoneal cavity and potential adhesions from previous transabdominal surgeries. This approach grants direct access to the hilar structures without any kidney mobilisation and would hypothetically give easier access to posterior tumours. The confined retroperitoneal space would contain any potential bleeding or urine leaks, thereby decreasing postoperative complications [11]. Nevertheless, the retroperitoneal approach is more challenging due to the confined space and less familiar landmarks.

In order to determine the potential superiority of one approach over the other, we carried out a systematic review of the literature in order to compare the two robotic approaches according to several per- and postoperative criteria.

# Materials and methods

#### Search strategies and study selection

All studies comparing transperitoneal robot-assisted partial nephrectomy (TRAPN) versus retroperitoneal robotassisted partial nephrectomy (RRAPN) were considered for inclusion.

A systematic review of the literature was performed up to May 2020, in accordance with the Cochrane Guidelines and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The bibliographic databases searched were PubMed, Cochrane, Ovid and Scopus. No language restrictions were applied.

A review protocol was established prior to the study. The PICO model used was as follows: the study population (P) consisted of patients with kidney tumours who underwent RRAPN (I) or TRAPN (C). Outcomes of interest were perioperative outcomes (O), as described below. Identification and selection of the studies were conducted according to PRISMA criteria (www.prisma-statement.org) (Fig. 1). Separate searches were performed using a combination of the search terms 'nephron-sparing', 'retroperitoneal', 'retroperitoneoscopic', 'robotic partial nephrectomy'.

A total of 37 potential publications were identified and 24 articles were eliminated after screening of the abstracts (5 were review articles, 3 were rejected due to low quality and 16 were not relevant). Thirteen full-text articles were assessed for eligibility and 2 were subsequently excluded due to a lack of sufficient data. Eleven studies were finally included in the quantitative synthesis (systematic review).

#### **Selection criteria**

Two of the authors (AB and EA) performed the article selection. Only original studies comparing the outcomes of RRAPN and TRAPN for renal tumours were included. The article titles and abstracts were first reviewed to ascertain whether they fulfilled the inclusion criteria. For those passing the first screening, a full-text analysis was performed to confirm inclusion. Studies without primary data (letters to the editor/authors, case reports and commentaries) and conference abstracts were not considered. The references of collected studies were reviewed manually in order to identify additional studies of interest.

#### **Quality assessment of studies**

Each study was classified according to the level of evidence (http://www.cebm.net/explanation-2011-ocebm-levels-evidence/). The quality of the studies was determined



Fig. 1 PRISMA flow diagram

using the Newcastle–Ottawa scale for non-randomised controlled trials (http://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp). The maximum score for each study is 9, with studies scoring < 5 identified as containing at high risk of bias.

#### **Risk of bias for observational studies**

Non-randomised studies were also assessed for a risk of bias. Due to the inherently higher risk of selection bias in non-randomised studies, the Cochrane risk of bias tool (ROBINS-1 tool) was used to assess bias in included non-randomised studies, with the addition of pre-specified confounders. The confounders considered were: age, RENAL score, tumour size, ASA or CCI score and body mass index (BMI) (Fig. 2).

#### Data extraction and analysis

All studies that fulfilled the inclusion criteria were identified and reviewed. Disagreement was resolved by consensus.

Data were extracted from each selected study. Baseline demographics (age, BMI, ASA or CCI score, tumour size, RENAL nephrometry score), intraoperative data (operative time, estimated blood loss, warm ischaemia time) and postoperative outcomes (major complications according to Clavien–Dindo, length of hospital stay (LOS) and positive surgical margin rate) were recorded.

For continuous outcomes, the weighted mean difference (WMD) was used as a summary measure, whereas the odds ratio (OR) or risk ratio (RR) with 95% confidence intervals (CI) was calculated for binary variables. RR was preferred in cases of a high number of events to avoid overestimation. As only means and standard deviations





(SD) are permitted for the computational portion of metaanalyses, a validated mathematical model was used to convert median (range) to mean (SD) for studies reporting medians and ranges. The Mantel–Haenszel Chi<sup>2</sup> test was used for continuous data and expressed as the WMD with 95% CI, and for dichotomous data inverse variance was used and expressed as OR or RR with 95% CI. *p* value was deemed significant if <0.05. Heterogeneity was analysed using a Chi<sup>2</sup> test on N – 1 degrees of freedom, with an alpha risk of 0.05 used for statistical significance, and with the I2 test [12].

Pooled estimates were calculated using the randomeffect model to account for study heterogeneity. Evaluation of potential publication bias was done by funnel plot analysis for each outcome. All statistical analyses were performed using Review manager 5 (Cochrane Collaboration, Oxford, UK).

# Results

# Description of included studies and quality assessment

Eleven studies, published between 2013 and 2020, were identified and included in the analysis (Table 1) [13–23]. There were no randomised clinical trials. Three studies were observational, retrospective, case–control studies, five were retrospective, matched cohort studies and three were prospective, non-randomised studies. Study quality was high for all studies and ranged between 7 and 8. Due to small number of studies, visual assessment was unlikely to be accurate, but no obvious publication bias was observed.

Table 1 De	mographics of the su	tudy populations in	the studies ar	nalysed						
Study/year	Design	Setting	TRAP N (N	) RRAPN (N)	Age	ASA/CCI	Renal score	Tumour size	BMI	Study quality
[13]/2013	Retrospective	Multicentre UK	59	44	Median (IQR) 60.5 (39–87) vs. 63.3 (38–80) ( <i>p</i> =0.227)	NA	Median (IQR) 5.5 (3–9) vs. 5.5 (4–10) ( <i>p</i> =0.82)	Median (IQR) 3.07 (1–7.2) vs. 2.84 (6.2–1.1) ( <i>p</i> =0.39)	NA	2
[14]/2013	Prospective, non- randomised	Single-centre Japan	16	10	Median (IQR) 70 (35–84) vs. 60.5 (46–82) ( <i>p</i> =0.769)	NA	Mean (SD) 7.4 $\pm$ 1.65 vs. 6.9 $\pm$ 1.29 ( $p$ =0.777)	Mean (SD) $3.36 \pm 1.1$ vs. $2.21 \pm 0.55$ (p = 0.05)	Mean (SD) 22.7 $\pm$ 2.94 vs. 23.2 $\pm$ 2.23 ( $p = 0.60$ )	×
[15]/2014	Retrospective matched pair	Single-centre South Korea	57	50	Median (IQR) 50.0 (41–57) vs. 54.5 (42.75–61.25) ( <i>p</i> =0.069)	ASA ≥ 2: 51% vs. 48% ( <i>p</i> =0.552)	Mean (SD) $6.6 \pm 1.5$ vs. $6.0 \pm 1.6$ ( $p = 0.072$ )	Mean (SD) 2.7 $\pm$ 1.3 vs. 2.8 $\pm$ 1.1 ( $p$ =0.20)	Mean (SD) 24.5 $\pm$ 2.8 vs. 24.7 $\pm$ 2.8 ( $p = 0.64$ )	×
[16]/2015	Retrospective	Single-centre USA	76	116	Mean (SD) 58.2 $\pm$ 11.8 vs. 57.2 $\pm$ 12.2 ( $p = 0.40$ )	$CCI \ge 2.22\%$ vs. 26% (p = 0.77)	Median 8 vs. 8 RENAL ( <i>p</i> = 0.93)	Mean (SD) 2.54 $\pm$ 1.44 vs. 2.48 $\pm$ 1.14 ( $p$ = 0.94)	BMI > 30, n = 37/97 (38%) vs. 57/116 (49%) $(p = 0.11)$	7
[17]/2017	Retrospective	Two-centre USA	263	141	Mean (SD) 58 $\pm$ 15 vs. 59.3 $\pm$ 14 ( $p$ =0.40)	NA	Mean (SD) $7.4 \pm 1.7$ vs. $7.2 \pm 1.9$ (p = 0.503)	Mean (SD) $3.1 \pm 1.8$ vs. $2.9 \pm 1.7$ (p=0.122)	Mean (SD) 28.6 $\pm$ 6.4 vs. 29.8 $\pm$ 6.7 ( $p$ =0.155)	٢
[18]/2017	Retrospective matched pair	Multicentre USA	296	74	Median (IQR) 59 (52–66) vs. 60 (50–65) ( <i>p</i> =0.92)	Median (IQR) ASA 2 $(2-3)$ vs. 2 $(2-3)$ (p=0.56)	Median (IQR) 7 (6–9) vs. 8 (6–9) RENAL ( $p$ =0.32)	Median (IQR) 2.5 (1.9–3.5) vs. 2.4 (1.9– 3.3) ( <i>p</i> =0.59)	Median (IQR) 29.4 (25.1– 33.0) vs. 30.0 (25.1–33.9 ( <i>p</i> =0.42)	×
[19]/2017	Retrospective matched pair	Two-centre USA	78	78	(p=0.49)	(p=0.795)	(p = 0.631)	NA	BMI > 30 $(p = 0.273)$	œ
[20]/2018	Prospective matched pair	Multicentre USA	394	66	Median (IQR) 61 (51–71) vs. 61 (55–68) (p=0.7)	ASA ≥ 2 86.8% vs. 90.2% ( <i>p</i> =0.7)	Intermediate 36% vs. 36.9%; High 64% vs. 63.1% $(p = 0.5)$	Median (IQR) 3.2 (2.3-4.5) vs. 3.0 (2.3- 4.2) ( <i>p</i> =0.2)	Median (IQR) 27.6 (24.8– 31.7) vs. 28.7 (25.8–32.5) ( <i>p</i> =0.6)	×
[21]/2019	Retrospective matched pair	Single-centre USA	157	157	Median (IQR) 61 (50–69) vs. 61 (53–68) (p=0.651)	Median (IQR) (CCI) $3 (2-4)$ vs. $3 (2-4)$ (p=0.053)	Median (IQR) 7 (5–8) vs. 7 (6–8) RENAL ( $p$ =0.308)	Median (IQR) 3.0 (2.2–4.1) vs. 2.9 (2.1– 4.3) ( <i>p</i> =0.741)	Median (IQR) 29.1 (25.8– 33.3) vs. 28.8 (25.6–33.1) ( <i>p</i> =0.996)	×
[22]/2019	Retrospective matched pair	Single-centre USA	263	281	Mean (SD) $60 \pm 12$ vs. $60 \pm 12$ (p=0.79)	Mean (SD) (CCI) $3.6\pm 2$ vs. $3.7\pm 1.9$ ( $p=0.5$ )	Mean (SD) 5.6 $\pm 2.7$ vs. 5.7 $\pm 2.6$ (p=0.5)	Mean (SD) $3.3 \pm 1.7$ vs. $3.1 \pm 1.5$ (p=0.3)	Mean (SD) $30.3 \pm 6.9$ vs. $29.7 \pm 5.8$ (p = 0.28)	∞

Study/year D	lesign	Setting	TRAP N (	(N) RRAPN	(N) Age	ASA/CCI	Renal score	Tumour size	BMI	Study quality
[23]/2020 P	rospective matched pair	Single-centre Japan	145	24	Mean (SD) 55 $\pm$ 12 vs. 55 $\pm$ 14 ( $p = 0.34$ )	ASA≥2 87% vs. 83% ( <i>p</i> =0.70)	NA	Mean (SD) $3.1 \pm 1.3$ vs. $3.0 \pm 1.2$ (p = 0.40)	Mean (SD) $25 \pm 4.0$ vs. $24 \pm 3.7$ (p = 0.55)	×

# **Demographics and clinical characteristics**

Among the 3139 patients included, 1087 underwent RRAPN and 2052 underwent TRAPN. There was no significant difference in age or BMI between the two groups (age, p = 0.36, WMD: -0.60 [95% CI - 1.90-0.70]; BMI, *p* = 0.98, WMD: 0.01 [95% CI-0.91-0.93]) (Fig. 3a, b). There was no significant difference between the two groups in terms of tumour size (p=0.06, WMD: 0.21 [95% CI - 0.01 - 0.42] and RENAL score (p=0.20, WMD: 0.14 [95% CI-0.07-0.36] (Fig. 3c, d). The demographics of the study populations are summarised in Table 1.

# **Outcomes**

### Clavien–Dindo $\geq$ 3 complication rates

A fixed model was used for this analysis as there was a low degree of heterogeneity  $(I^2 = 21\%)$ . There was no significant difference in  $\geq$  3 Clavien–Dindo complication rates between the two approaches (WMD: 0.79 [95% CI 0.46-1.33]; p = 0.37) (Fig. 4a).

# **Operative time**

All studies had data available on operative time. A random model was used for analysis as there was a high degree of heterogeneity  $(I^2 = 91\%)$ . There was a statistically significant difference in operative time between the two approaches (WMD: 16.29 [95% CI 2.52–30.05]; *p*=0.02) (Fig. 4b).

### Estimated blood loss

All the studies had data available on estimated blood loss. A random model was used for this analysis as there was a moderate degree of heterogeneity ( $I^2 = 70\%$ ). There was a statistically significant difference in estimated blood loss between the two approaches (WMD: 29.73 [95% CI 24.69–34.77]; p < 0.00001) (Fig. 4c).

### Warm ischaemia time

Ten studies had data available on warm ischaemia time. A random model was used for this analysis as there was a moderate degree of heterogeneity ( $I^2 = 56\%$ ). There was no significant difference in warm ischaemia time between the two approaches (WMD: 0.10 [95% CI - 0.45 - 0.66]; p = 0.37) (Fig. 4d).

### Positive margin rates

Ten studies had data available on positive surgical margin rates. A fixed model was used for this analysis as

#### (a) Age

	Exp	eriment	tal	C	Control			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
tanaka 2013	64.75	12.25	16	62.25	10.44	10	2.2%	2.50 [-6.33, 11.33]	2013	
Hughes Hallet 2013	60.5	12	59	63.3	10.5	44	8.9%	-2.80 [-7.16, 1.56]	2013	
Choo 2014	50	11.85	57	54.5	13.7	50	7.1%	-4.50 [-9.39, 0.39]	2014	
kim 2015	58.2	11.8	97	57.2	12.1	116	16.3%	1.00 [-2.22, 4.22]	2015	
stroup 2017	58	15	263	59.3	14	141	19.5%	-1.30 [-4.24, 1.64]	2017	
Mittakanti 2019	60	12	263	60	12	281	41.4%	0.00 [-2.02, 2.02]	2019	-
Takagi 2020	55	12	145	55	14	24	4.8%	0.00 [-5.93, 5.93]	2020	
Total (95% CI)			900			666	100.0%	-0.60 [-1.90, 0.70]		•
Heterogeneity. $Chi^2 =$	5.44, df	= б (Р	= 0.49	); $ ^2 = 0$	%				Ŀ	20 -10 0 10 20
Test for overall effect:	Z = 0.9	1 (P = 0)	0.36)							Favours Transperitoneal Favours retroperitoneal

# (b) BMI

		TP			RP			Mean Difference			Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year		IV, Random, 95% CI	
tanaka 2013	22.7	2.8	16	23.2	2.23	10	16.4%	-0.50 [-2.45, 1.45]	2013			
Choo 2014	24.5	28	57	24.7	2.8	50	1.5%	-0.20 [-7.51, 7.11]	2014	+		
stroup 2017	28.6	6.4	263	29.8	6.7	141	26.7%	-1.20 [-2.55, 0.15]	2017			
Mittakanti 2019	30.3	6.9	263	29.7	5.8	281	33.9%	0.60 [-0.47, 1.67]	2019			
Takagi 2020	25	4	145	24	3.7	24	21.3%	1.00 [-0.62, 2.62]	2020			
Total (95% CI)			744			506	100.0%	0.01 [-0.91, 0.93]				
Heterogeneity: Tau <sup>2</sup> =	0.34; (	:hi² =	5.94,	df = 4	(P = 0)	.20); I <sup>2</sup>	= 33%			-4	-2 4 2	4
Test for overall effect:	Z = 0.0	)2 (P	= 0.98	)						•	Favours [transperitoneal] Favours [retroperitoneal]	

#### (c) Tumor size

		TP			RP			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
tanaka 2013	3.36	1.1	16	2.21	0.56	10	8.3%	1.15 [0.51, 1.79]	2013	
Hughes Hallet 2013	3.07	1.55	59	2.84	1.28	44	10.5%	0.23 [-0.32, 0.78]	2013	
Choo 2014	2.7	1.3	57	2.8	1.1	50	13.3%	-0.10 [-0.55, 0.35]	2014	
kim 2015	2.54	1.44	97	2.48	1.114	116	17.6%	0.06 [-0.29, 0.41]	2015	
stroup 2017	3.1	1.8	263	2.9	1.7	141	17.4%	0.20 [-0.16, 0.56]	2017	
Mittakanti 2019	3.3	1.7	263	3.1	1.5	281	21.8%	0.20 [-0.07, 0.47]	2019	+
Takagi 2020	3.1	1.3	145	3	1.2	24	11.1%	0.10 [-0.42, 0.62]	2020	<del></del>
Total (95% CI)	0.04	-1.2	900	-16 C	(D ) )	666	100.0%	0.21 [-0.01, 0.42]		· · · · · ·
Test for overall effect:	Z = 1.2	90 (P =	0.06)	ui = 6	(r = 0.(	, I <sup>-</sup> =	• 42%		-2	-'1 0 1 2' Favours [transperitoneal] Favours [retroperitoneal]

#### (d) RENAL score

		TP			RP			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Hughes Hallet 2013	5.5	1.5	59	5.5	1.5	44	13.6%	0.00 [-0.59, 0.59]	2013	
tanaka 2013	7.4	1.65	16	6.9	1.29	10	3.6%	0.50 [-0.64, 1.64]	2013	
Choo 2014	6.6	1.5	57	б	1.6	50	13.4%	0.60 [0.01, 1.19]	2014	
kim 2015	8	2.22	97	8	2.22	116	13.0%	0.00 [-0.60, 0.60]	2015	
stroup 2017	7.4	1.7	263	7.2	1.9	141	33.1%	0.20 [-0.17, 0.57]	2017	
Mittakanti 2019	5.6	2.7	263	5.7	2.6	281	23.4%	-0.10 [-0.55, 0.35]	2019	
Total (95% CI)			755			642	100.0%	0.14 [-0.07, 0.36]		-
Heterogeneity: Tau <sup>2</sup> =	0.00;	Chi <sup>2</sup> =	4.36, d	f = 5 (F	0 = 0.5	50); I <sup>2</sup> =	• 0%		F	
Test for overall effect:	Z = 1.2	28 (P =	0.20)							Favours [transperitoneal] Favours [retroperitoneal]

Fig. 3 Comparison of demographics and clinical characteristics between the two groups

there was a low degree of heterogeneity ( $I^2 = 0\%$ ). There was no significant difference in positive surgical margin rates between the two approaches (WMD: 0.68 [95% CI 0.41–1.12]; p = 0.13) (Fig. 4e).

#### Length of hospital stay

Eight studies had data available on LOS. A random model was used for this analysis as there was a very high degree of

#### (a) Clavien-Dindo ≥3 complication rates

	TP		RP			Odds Ratio			Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year		M-H, Random, 95% CI	
tanaka 2013	1	16	0	10	2.4%	2.03 [0.08, 54.83]	2013			_
Hughes Hallet 2013	3	59	0	44	2.9%	5.51 [0.28, 109.54]	2013			$\rightarrow$
Choo 2014	0	57	0	50		Not estimable	2014			
kim 2015	7	97	5	116	14.3%	1.73 [0.53, 5.62]	2015			
Maurice 2016	9	523	4	87	14.0%	0.36 [0.11, 1.21]	2016			
Laviana 2017	5	78	4	78	11.7%	1.27 [0.33, 4.91]	2017			
stroup 2017	7	263	4	141	13.3%	0.94 [0.27, 3.26]	2017			
Paulucci 2018	5	157	8	157	15.1%	0.61 [0.20, 1.92]	2018			
Arora 2018	1	394	2	99	4.4%	0.12 [0.01, 1.38]	2018			
Mittakanti 2019	6	263	14	281	18.7%	0.45 [0.17, 1.18]	2019			
Takagi 2020	13	145	0	24	3.2%	4.99 [0.29, 86.77]	2020			
Total (95% CI)		2052		1087	100.0%	0.79 [0.46, 1.33]			•	
Total events	57		41							
Heterogeneity. Tau <sup>2</sup> =	0.14; Cł	$ni^2 = 11$	L.32, df =	= 9 (P =	= 0.25); 1	2 = 21%		0.01		100
Test for overall effect:	Z = 0.90	P = 0	.37)					0.01	Favours (transperitoneal) Favours (retroperitoneal	100
									ravours [transperitorical] ravours [retroperitorieal	1

#### (b) Operative time

	Favours t	ransperito	oneal	Retro	periton	eal		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
tanaka 2013	239	63	16	193	40.6	10	5.6%	46.00 [6.17, 85.83]	2013	
Hughes Hallet 2013	195.3	57.5	59	148.5	36.75	44	8.8%	46.80 [28.55, 65.05]	2013	
Choo 2014	150	57.4	57	120	38.33	50	8.8%	30.00 [11.70, 48.30]	2014	
kim 2015	149	44	97	152	44	116	9.7%	-3.00 [-14.87, 8.87]	2015	
Maurice 2016	176	58	523	176	59	87	9.5%	0.00 [-13.36, 13.36]	2016	
Laviana 2017	191.1	60.3	78	167	44.3	78	9.1%	24.10 [7.49, 40.71]	2017	
stroup 2017	231.7	70.4	263	217.2	61.9	141	9.5%	14.50 [1.20, 27.80]	2017	<b>_</b>
Arora 2018	170	58	394	160	59	99	9.6%	10.00 [-2.96, 22.96]	2018	
Paulucci 2018	157	43.5	157	185	48.2	157	9.9%	-28.00 [-38.16, -17.84]	2018	
Mittakanti 2019	191	53	263	162	50	281	10.0%	29.00 [20.33, 37.67]	2019	
Takagi 2020	151	34	145	124	29	24	9.6%	27.00 [14.15, 39.85]	2020	
Total (95% CI)			2052			1087	100.0%	16.29 [2.52, 30.05]		◆
Heterogeneity. Tau <sup>2</sup> =	472.60; Ch	i <sup>2</sup> = 111.5	5, df =	10 (P <	0.0000	1);  2 =	91%			
Test for overall effect:	Z = 2.32 (P	= 0.02)								Favours transperitoneal Favours retroperitoneal

# (c) Estimated blood loss

	Trans	peritor	eal	Retro	periton	eal		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
tanaka 2013	33	41.1	16	13.5	7.5	10	6.0%	19.50 [-1.17, 40.17]	2013	
Hughes Hallet 2013	395.1	770	59	88	395	44	0.0%	307.10 [78.57, 535.63]	2013	
Choo 2014	150	111.1	57	100	102.8	50	1.5%	50.00 [9.46, 90.54]	2014	
kim 2015	100	74.07	97	100	111.1	116	4.1%	0.00 [-25.02, 25.02]	2015	
Maurice 2016	190	239	523	150	62	87	4.3%	40.00 [15.72, 64.28]	2016	
Laviana 2017	299	383.9	78	203.4	575.9	78	0.1%	95.60 [-58.00, 249.20]	2017	
stroup 2017	168.7	64.9	263	120	43.3	141	22.6%	48.70 [38.09, 59.31]	2017	
Arora 2018	125	40	394	100	30	99	50.4%	25.00 [17.89, 32.11]	2018	
Paulucci 2018	100	170.8	157	100	96.7	157	2.7%	0.00 [-30.70, 30.70]	2018	
Mittakanti 2019	171	163	263	134	154	281	3.6%	37.00 [10.31, 63.69]	2019	
Takagi 2020	52	45	145	33	55	24	4.7%	19.00 [-4.19, 42.19]	2020	
Total (95% CI)	22.07	16 10	2052	00031	2 700	1087	100.0%	29.73 [24.69, 34.77]		· · · · · · · · · · · · · · · · · · ·
Test for every lieffect	33.07, 0		(F = 0.	00033;1	r = 70%	×				-100 -50 0 50 100
rest for overall effect.	2 = 11.	>> (P <	0.0000	)1)						Favours Transperitoneal Favours Retroperitoneal

Favours transperitoneal Mean Difference Mean Difference Retroperitoneal 
 Nean Difference

 IV, Random, 95% CI
 Year

 46.00 [6.17, 85.83]
 2013

 46.80 [28.55, 65.05]
 2013

 30.00 [11.70, 48.30]
 2014

 -3.00 [-14.87, 88.7]
 2015

 0.00 [-13.36, 13.36]
 2016

 24.10 [7.49, 40.71]
 2017

 14.50 [1.20, 27.80]
 2017

 20.00 [-2.36, 22.36]
 2018

 29.00 [20.33, 37.67]
 2019

 27.00 [14.15, 39.85]
 2020

 SD
 Total
 Weight

 40.6
 10
 5.6%

 5.75
 44
 8.8%
SD Total Mean 16 193 Study or Subgroup Mean IV. Random, 95% CI 239 tanaka 2013 63 40.6 193 40.6 148.5 36.75 120 38.33 152 44 176 59 167 44.3 Hughes Hallet 2013 Choo 2014 195.3 150 149 176 191.1 59 57 97 57.5 57.4 44 58 60.3 70.4 58 43.5 53 34 8.8% 8.8% 9.7% 9.5% 9.1% 9.5% 50 kim 2014 kim 2015 Maurice 2016 Laviana 2017 stroup 2017 Arora 2018 Paulucci 2018 116 87 78 523 176 78 167 263 217.2 44.3 61.9 59 48.2 50 29 141 99 157 231.7 170 157 394 157 160 185 9.6% 9.9% Mittakanti 2019 Takagi 2020 191 151 162 124 281 24 10.0% 9.6% 263 145 Total (95% CI) 16.29 [2.52, 30.05] 2052 1087 100.0% Heterogeneity: Tau<sup>2</sup> = 472.60; Chi<sup>2</sup> = 111.55, df = 10 (P < 0.00001); l<sup>2</sup> = 91% Test for overall effect: Z = 2.32 (P = 0.02) -100 -50 50 100 Favours transperitoneal Favours retroperitoneal

Fig. 4 Comparison of outcomes between the two groups

#### (d) Warm ischemia time

	trans	perito	neal	Retro	peritor	neal		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
tanaka 2013	24.3	9.07	16	24.7	8.35	10	0.7%	-0.40 [-7.22, 6.42]	2013	
Hughes Hallet 2013	19.1	8.2	59	22.1	6.8	44	3.6%	-3.00 [-5.90, -0.10]	2013	
Choo 2014	26.2	8.5	57	22.6	9	50	2.8%	3.60 [0.27, 6.93]	2014	
Maurice 2016	19	8.5	296	21	6.9	74	9.0%	-2.00 [-3.85, -0.15]	2016	
stroup 2017	23.1	5.4	263	22.8	5.1	141	27.0%	0.30 [-0.77, 1.37]	2017	+
Laviana 2017	21.9	11.1	78	20.8	8.3	78	3.2%	1.10 [-1.98, 4.18]	2017	
Paulucci 2018	17	7.6	394	17	7.5	99	11.1%	0.00 [-1.66, 1.66]	2018	
Arora 2018	17	6.8	157	17	8.2	157	11.0%	0.00 [-1.67, 1.67]	2018	
Mittakanti 2019	18	6	263	18	7	281	25.6%	0.00 [-1.09, 1.09]	2019	-+-
Takagi 2020	17	5.4	145	14	5.2	24	6.0%	3.00 [0.74, 5.26]	2020	
Total (95% CI)			1728			958	100.0%	0.10 [-0.45, 0.66]		•
Heterogeneity: Chi <sup>2</sup> =	20.55,	df = 9	(P = 0.	01); l <sup>2</sup> =	56%					-10 -5 0 5 10
Test for overall effect:	Z = 0.3	7 (P =	0.71)							Favours [transperitoneal] Favours [retroperitoneal]

#### (e) Positive margin rates

	Transperit	oneal	Retroperito	neal		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M-H, Fixed, 95% CI
Hughes Hallet 2013	0	16	1	10	4.9%	0.19 [0.01, 5.20]	2013	· · · · · · · · · · · · · · · · · · ·
tanaka 2013	3	59	3	44	9.1%	0.73 [0.14, 3.81]	2013	
Choo 2014	1	57	0	50	1.4%	2.68 [0.11, 67.31]	2014	
Maurice 2016	5	296	1	74	4.4%	1.25 [0.14, 10.90]	2016	
Laviana 2017	2	78	4	78	10.8%	0.49 [0.09, 2.74]	2017	
stroup 2017	11	263	4	141	13.9%	1.50 [0.47, 4.78]	2017	
Arora 2018	2	394	2	99	8.9%	0.25 [0.03, 1.78]	2018	
Paulucci 2018	3	157	5	157	13.6%	0.59 [0.14, 2.52]	2018	
Mittakanti 2019	5	263	8	281	21.1%	0.66 [0.21, 2.05]	2019	
Takagi 2020	0	145	2	24	11.8%	0.03 [0.00, 0.67]	2020	·
Total (95% CI)		1728		958	100.0%	0.68 [0.41, 1.12]		•
Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	32 8.42, df = 9 Z = 1.52 (P	9 (P = 0. = 0.13)	30 49); I <sup>2</sup> = 0%					0.005 0.1 1 10 200 Favours (transperitoneal) Favours (retroneritoneal)

#### (f) Length of hospital stay

	Transp	erito	neal	Retro	peritor	neal		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Hughes Hallet 2013	9.5	7.8	59	14	14.2	44	0.0%	-4.50 [-9.14, 0.14]	2013	
Maurice 2016	2.6	1.2	523	2.2	0.9	87	9.6%	0.40 [0.18, 0.62]	2016	-
Laviana 2017	2.7	1.7	78	1.8	0.9	78	2.4%	0.90 [0.47, 1.33]	2017	
stroup 2017	2.5	0.7	263	2.2	0.6	141	26.3%	0.30 [0.17, 0.43]	2017	-
Arora 2018	3	0.7	394	1	0.6	99	23.8%	2.00 [1.86, 2.14]	2018	
Paulucci 2018	2	0.7	157	1	0.6	157	21.4%	1.00 [0.86, 1.14]	2018	
Mittakanti 2019	1.9	1.3	263	1.7	0.9	281	12.5%	0.20 [0.01, 0.39]	2019	-
Takagi 2020	4	1.2	145	3.3	0.67	24	4.0%	0.70 [0.37, 1.03]	2020	+
Total (95% CI)			1882			911	100.0%	0.88 [0.81, 0.95]		)
Heterogeneity. Chi <sup>2</sup> =	410.95,	df =	7 (P < 0	0.00001	$(1);  ^2 =$	98%				
Test for overall effect:	Z = 25.8	37 (P	< 0.00	001)						Favours [experimental] Favours [control]

Fig. 4 (continued)

heterogeneity ( $l^2 = 98\%$ ). The analysis favoured the retroperitoneal approach with a lower mean LOS (WMD: 0.88 [95% CI 0.81–0.95]; p < 0.00001) (Fig. 4f).

# Discussion

Nephron-sparing surgery has become the gold standard for a wide range of renal tumours, mainly classified as T1 (<7 cm), but also for selected patients with T2 tumours, if technically feasible. Until the recent development of robotic

surgery open partial nephrectomy was widely used, but technical difficulties existed with the laparoscopic approach, mainly with suturing of the tumour bed with limited instrument manipulation. With a reduced learning curve, robotic partial nephrectomy, reported for the first time in 2004, has rapidly gained its place in the management of renal masses [24].

Both the retroperitoneal and transperitoneal approach have been reported. The choice between these two techniques is based mainly on the surgeon's preference and his/ her training and experience. More robotic surgeons seem to be attracted to the transperitoneal approach due to the large working space and the ease of instrument movement, especially during suturing. Nevertheless, this technique requires colonic dissection with potential postoperative ileus. The presence of intra-peritoneal adhesions increases the operative time. The retroperitoneal approach has the inconvenience of working in a confined space with an "unfamiliar" anatomy for a large majority of surgeons. It has been hypothesised that this approach would grant easier access to the hilar structures and posteriorly localised tumours without the need for complete renal dissection. It would also confine any possible postoperative bleeding or urine leakage.

Our study presents the most up to date and largest cumulative analysis of studies comparing TRAPN with RRAPN. Overall, our findings suggest equivalent outcomes with the two approaches, in terms of surgical quality or short-term oncological or functional outcomes. There were no significant differences between TRAPN and RRAPN in terms of tumour size (WMD: 0.21 [95% CI - 0.01-0.42]; p=0.06) or RENAL score (WMD: 0.14 [95% CI-0.07-0.36]; p=0.20). Both operative time (WMD 16.29 min [95% CI 2.52-30.05]; p = 0.02) and estimated blood loss (WMD: 29.73 ml [95% CI 24.69–34.77]; p < 0.00001) were significantly lower in the retroperitoneal group. LOS was also significantly shorter in the retroperitoneal group (WMD: 0.88 days [95% CI 0.81–0.95]; p < 0.00001). No differences were found in major postoperative complications (Clavien–Dindo  $\geq 3$ ; p=0.37), warm ischaemia time (p=0.37) and positive surgical margins (p=0.13).

The clinical impact of these differences seems to be negligible however, with respect to functional recovery and oncological efficacy. The impact on quality of life indices remains to be determined.

Not surprisingly, with a more direct approach to the hilum and posterior tumours, the current review reveals a shorter operative time and lower estimated blood loss with RRAPN and thus an advantageous shorter LOS [25].

RRAPN still lags behind TRAPN with regard to its maturity and experience as an approach, suggesting that a learning curve effect may influence contemporary outcomes explaining its non-superiority in terms of oncological and functional outcomes.

Our study has several limitations. Despite representing a robust statistical tool, meta-analyses carry intrinsic biases and randomised controlled trials should ideally be included. The main limitation is the non-randomised nature of the studies analysed. Most of the studies were either retrospective or prospective non-randomised trials, albeit of good quality. Only two of the studies in this review were prospective, matched-paired, highlighting a selection bias. Furthermore, some parameters were not assessed or available to analyse in our study. For example, positive surgical margins were assessed while functional outcome analysis was not possible. It was also not possible to account for existing differences between institutions and surgeons in terms of surgical technique and expertise, as well as protocols of perioperative management and follow-up. It would be interesting to assess how the introduction of the Xi system or the single port system might facilitate or influence clashing issues compared to the Si system.

A recent review carried out by Mclean et al. suggested a slight advantage of RRAPN in terms of LOS compared to TRAPN, especially for posterior tumours. RRAPN did not appear to offer any advantage over TRAPN for other perioperative outcomes such as warm ischaemia time, operative time and estimated blood loss. The surgical margin rates and morbidity of the two approaches appear to be similar [26].

The current review would suggest that the two approaches are equivalent and recruitment into trials is, therefore, feasible. In keeping with the IDEAL guidelines, future researchers must attempt to achieve adequately powered, expertise based, multi-surgeon and multi-centric studies comparing TRAPN and RRAPN [26].

Despite all these limitations, this review provides the most up to date and best available evidence in the field, and therefore, our findings can be used as a reference for further clinical investigations. Comparative prospective, randomised, multicentre or multinational studies are needed for a more robust choice between the two approaches when planning RAPN.

# Conclusion

RRAPN offers, in select patients, similar outcomes to those of TRAPN. Furthermore, RRAPN may be particularly advantageous for some patients since it is associated with a reduced operative time and LOS. Ideally, surgeons should be familiar and competent in both approaches when offering RAPN to their patients, adopting a risk-stratified and patientcentred individualised approach, dependent on patient and tumour characteristics. Further randomised, controlled trials and high-quality observational studies with larger sample sizes and long-term follow-up are needed for an informed decision on the best approach.

Author contributions AB: project development, data collection, manuscript writing, EA: data collection, data analysis, SM: manuscript writing, MR: manuscript editing, FB: project development, manuscript editing.

Funding No funds were provioded for this publication.

Availability of data and material Not applicable.

Code availability Not applicable.

#### Declarations

**Conflict of interest** The authors have not disclosed any competing interests.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

# References

- Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170:2217–2220. https://doi. org/10.1097/01.ju.0000095475.12515.5e
- Lerner SE, Hawkins CA, Blute ML et al (2002) Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. 1996. J Urol 167:884– 890. https://doi.org/10.1016/s0022-5347(02)80290-7
- Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM (2006) Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology 67:260–264. https://doi.org/10. 1016/j.urology.2005.08.057
- Pavan N, Derweesh IH, Mir CM et al (2017) Outcomes of laparoscopic and robotic partial nephrectomy for large (>4 cm) kidney tumors: systematic review and meta-analysis. Ann Surg Oncol 24:2420–2428. https://doi.org/10.1245/ s10434-017-5831-5
- Gill IS, Kamoi K, Aron M, Desai MM (2010) 800 laparoscopic partial nephrectomies: a single surgeon series. J Urol 183:34– 41. https://doi.org/10.1016/j.juro.2009.08.114
- Miller DC, Hollingsworth JM, Hafez KS, Daignault S, Hollenbeck BK (2006) Partial nephrectomy for small renal masses: an emerging quality of care concern? J Urol 175:853–858. https:// doi.org/10.1016/S0022-5347(05)00422-2
- Yu HY, Hevelone ND, Lipsitz SR, Kowalczyk KJ, Hu JC (2012) Use, costs and comparative effectiveness of robotic assisted, laparoscopic and open urological surgery. J Urol 187:1392– 1398. https://doi.org/10.1016/j.juro.2011.11.089
- Mottrie A, De Naeyer G, Schatteman P, Carpentier P, Sangalli M, Ficarra V (2010) Impact of the learning curve on perioperative outcomes in patients who underwent robotic partial nephrectomy for parenchymal renal tumours. Eur Urol 58:127– 132. https://doi.org/10.1016/j.eururo.2010.03.045
- Ghani KR, Sukumar S, Sammon JD, Rogers CG, Trinh QD, Menon M (2014) Practice patterns and outcomes of open and minimally invasive partial nephrectomy since the introduction of robotic partial nephrectomy: results from the nationwide inpatient sample. J Urol 191:907–912. https://doi.org/10.1016/j. juro.2013.10.099
- Rai BP, Jones P, Tait C et al (2018) Is cryotherapy a genuine rival to robotic-assisted partial nephrectomy in the management of suspected renal malignancy? A systematic review and metaanalysis. Urology 118:6–11. https://doi.org/10.1016/j.urology. 2017.09.008
- Ghani KR, Porter J, Menon M, Rogers C (2014) Robotic retroperitoneal partial nephrectomy: a step-by-step guide. BJU Int 114:311–313. https://doi.org/10.1111/bju.12709
- 12. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The

Cochrane Collaboration, 2011. http://handbook.cochrane.org. Accessed Mar 2017.

- Hughes-Hallett A, Patki P, Patel N, Barber NJ, Sullivan M, Thilagarajah R (2013) Robot-assisted partial nephrectomy: a comparison of the transperitoneal and retroperitoneal approaches. J Endourol 27:869–874. https://doi.org/10.1089/end.2013.0023
- Tanaka K, Shigemura K, Furukawa J et al (2013) Comparison of the transperitoneal and retroperitoneal approach in robotassisted partial nephrectomy in an initial case series in Japan. J Endourol 27:1384–1388. https://doi.org/10.1089/end.2012.0641
- 15. Choo SH, Lee SY, Sung HH et al (2014) Transperitoneal versus retroperitoneal robotic partial nephrectomy: matched-pair comparisons by nephrometry scores. World J Urol 32:1523–1529. https://doi.org/10.1007/s00345-014-1312-7
- Kim EH, Larson JA, Potretzke AM, Hulsey NK, Bhayani SB, Figenshau RS (2015) Retroperitoneal robot-assisted partial nephrectomy for posterior renal masses is associated with earlier hospital discharge: a single-institution retrospective comparison. J Endourol 29:1137–1142. https://doi.org/10.1089/end. 2015.0076
- Stroup SP, Hamilton ZA, Marshall MT et al (2017) Comparison of retroperitoneal and transperitoneal robotic partial nephrectomy for Pentafecta perioperative and renal functional outcomes. World J Urol 35:1721–1728. https://doi.org/10.1007/ s00345-017-2062-0
- Maurice MJ, Kaouk JH, Ramirez D et al (2017) Robotic partial nephrectomy for posterior tumors through a retroperitoneal approach offers decreased length of stay compared with the transperitoneal approach: a propensity-matched analysis. J Endourol 31:158–162
- Laviana AA, Tan HJ, Hu JC, Weizer AZ, Chang SS, Barocas DA (2018) Retroperitoneal versus transperitoneal robotic-assisted laparoscopic partial nephrectomy: a matched-pair, bicenter analysis with cost comparison using time-driven activity-based costing. Curr Opin Urol 28:108–114. https://doi.org/10.1097/ MOU.000000000000483
- Arora S, Heulitt G, Menon M et al (2018) Retroperitoneal vs transperitoneal robot-assisted partial nephrectomy: comparison in a multi-institutional setting. Urology 120:131–137. https:// doi.org/10.1016/j.urology.2018.06.026
- Paulucci DJ, Beksac AT, Porter J et al (2019) A multi-institutional propensity score matched comparison of transperitoneal and retroperitoneal partial nephrectomy for cT1 posterior tumors. J Laparoendosc Adv Surg Tech A 29:29–34. https://doi. org/10.1089/lap.2018.0313
- Mittakanti HR, Heulitt G, Li HF, Porter JR (2020) Transperitoneal vs. retroperitoneal robotic partial nephrectomy: a matchedpaired analysis. World J Urol 38:1093–1099. https://doi.org/10. 1007/s00345-019-02903-7
- 23. Takagi T, Yoshida K, Kondo T et al (2020) Comparisons of surgical outcomes between transperitoneal and retroperitoneal approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: a propensity score-matched comparative analysis. J Robot Surg. https://doi.org/10.1007/s11701-020-01086-3. (published online ahead of print, 2020 May 1)
- Gettman MT, Blute ML, Chow GK, Neururer R, Bartsch G, Peschel R (2004) Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology 64:914–918. https://doi.org/10.1016/j. urology.2004.06.049
- 25. McLean A, Mukherjee A, Phukan C et al (2020) Trans-peritoneal vs. retroperitoneal robotic assisted partial nephrectomy in posterior renal tumours: need for a risk-stratified patient individualised approach. A systematic review and meta-analysis. J Robot Surg 14:1–9. https://doi.org/10.1007/ s11701-019-00973-8

Hirst A, Philippou Y, Blazeby J et al (2019) No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations. Ann Surg 269:211–220. https://doi.org/10.1097/SLA.00000000002794

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.